GSK-49653/097



A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C 8mg once daily on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
rosiglitazone
49653/097
Diabetes Mellitus, Type 2
Phase 3
 
An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2014